文献速递浆细胞疾病

真实世界多发性骨髓瘤人群中的衰弱与生活质量

Frailty and quality of life in a real-world multiple myeloma population.
PubMed 文献 · Br J Haematol · 2026-10-15

这项丹麦全国性纵向观察研究纳入681例新诊断或复发难治的症状性多发性骨髓瘤患者,按IMWG衰弱评分分为fit、intermediate-fit和frail,分析2017至2021年2年随访期间的患者报告结局。研究发现衰弱患者基线整体生活质量和躯体功能临床相关性地低于fit患者、疲乏更重;衰弱NDMM患者随访中整体生活质量和疼痛改善而躯体功能和疲乏不变,衰弱RRMM患者整体生活质量和疲乏不变、躯体功能恶化且疼痛加重。

要点

  • 真实世界衰弱骨髓瘤患者基线整体生活质量和躯体功能更差、疲乏更重。
  • 衰弱NDMM患者随访中整体生活质量和疼痛改善,躯体功能和疲乏无变化。
  • 衰弱RRMM患者随访中躯体功能恶化、疼痛加重,整体生活质量和疲乏无变化。

核心结论

  • 基于真实世界人群的结果显示,临床试验人群的生活质量结论不能直接外推至衰弱骨髓瘤患者。

研究设计与样本

  • 丹麦全国性纵向观察研究,纳入681例新诊断或复发难治的症状性多发性骨髓瘤患者。
  • 使用患者报告结局在2017至2021年间随访2年,按IMWG衰弱评分分为fit、intermediate-fit和frail。
  • 分析EORTC QLQ-C30、EORTC QLQ-CIPN20和SF12中预设生活质量域,采用线性混合模型并以临床相关性解读。

主要发现

  • 基线时衰弱患者较fit患者报告临床相关性地更低的整体生活质量和躯体功能,以及更重的疲乏。
  • 衰弱NDMM患者随访中整体生活质量和疼痛改善,而躯体功能和疲乏保持不变。
  • 衰弱RRMM患者随访中整体生活质量和疲乏不变,躯体功能恶化且疼痛加重。

临床怎么用

  • 对衰弱骨髓瘤患者的生活质量评估与干预应基于真实世界数据,而非直接套用临床试验结果。
  • 随访中应关注衰弱NDMM患者的躯体功能和疲乏,以及衰弱RRMM患者的躯体功能和疼痛变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Frailty is common in multiple myeloma (MM) and is associated with inferior outcomes. Knowledge on quality of life (QoL) primarily originates from clinical trials, where frail patients are often not included. In this nationwide, longitudinal observational study, QoL was assessed in 681 Danish patients with newly diagnosed MM (NDMM) or relapsed or refractory MM (RRMM) with symptomatic disease using patient-reported outcomes collected over 2 years of follow-up between 2017 and 2021. Patients were categorized as fit, intermediate-fit or frail according to the International Myeloma Working Group (IMWG) frailty score. Preselected QoL domains from the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core 30 (QLQ-C30), the Chemotherapy-Induced Peripheral Neuropathy module (EORTC QLQ-CIPN20) and the Short-form health survey (SF12) questionnaires were analysed using linear mixed models and interpreted in terms of clinical relevance. At inclusion, frail patients reported clinically relevant lower global QoL and physical functioning, and more fatigue compared to fit patients. Frail NDMM patients reported improvement in global QoL and pain during follow-up, whereas physical functioning and fatigue remained unchanged. Frail RRMM patients reported unchanged global QoL and fatigue, and deterioration in physical functioning and more pain during follow-up. Our results based on a real-world population show that QoL findings from clinical trial populations cannot directly be applied to frail patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Rydahl KFK, Möller S, Horsbøl TA, et al. Frailty and quality of life in a real-world multiple myeloma population. Br J Haematol. 2026. PMID: 42880361. doi:10.1111/bjh.70870

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。